Vanadium treatment of type 2 diabetes: a view to the future.
about
Why Antidiabetic Vanadium Complexes are Not in the Pipeline of "Big Pharma" Drug Research? A Critical ReviewThe metal face of protein tyrosine phosphatase 1BThe elements of life and medicinesVanadyl sulfate treatment stimulates proliferation and regeneration of beta cells in pancreatic isletsSodium vanadate combined with L-ascorbic acid delays disease progression, enhances motor performance, and ameliorates muscle atrophy and weakness in mice with spinal muscular atrophy.A thermodynamic model for vanadate in aqueous solution--equilibria and reaction enthalpies.Influence of fructose and fatty-rich diet combined with vanadium on bone marrow cellsCharacterization of aqueous formulations of tetra- and pentavalent forms of vanadium in support of test article selection in toxicology studies.Exposure to multiple metals from groundwater-a global crisis: geology, climate change, health effects, testing, and mitigation.Chimeric design, synthesis, and biological assays of a new nonpeptide insulin-mimetic vanadium compound to inhibit protein tyrosine phosphatase 1BThe Structural Basis of Action of Vanadyl (VO(2+)) Chelates in Cells.The anti-diabetic bis(maltolato)oxovanadium(IV) decreases lipid order while increasing insulin receptor localization in membrane microdomains.Coordination chemistry may explain pharmacokinetics and clinical response of vanadyl sulfate in type 2 diabetic patientsTrace elements in glucometabolic disorders: an update.Reactivity-activity relationships of oral anti-diabetic vanadium complexes in gastrointestinal media: an X-ray absorption spectroscopic study.Magnolia officinalis Extract Contains Potent Inhibitors against PTP1B and Attenuates Hyperglycemia in db/db MiceExploring Oxidovanadium(IV) Complexes as YopH Inhibitors: Mechanism of Action and Modeling Studies.Pharmacokinetic profile evaluation of di-μ-hydroxo-bis(quercetinatooxovanadium(IV)) complex.Effect of Ancillary Ligand on Electronic Structure as Probed by (51)V Solid-State NMR Spectroscopy for Vanadium-o-Dioxolene Complexes.Antidiabetic activity of zinc oxide and silver nanoparticles on streptozotocin-induced diabetic rats.Characterization and cytotoxic effect of aqua-(2,2',2''-nitrilotriacetato)-oxo-vanadium salts on human osteosarcoma cells.The challenges of trafficking hydrolysis prone metals and ascidians as an archetype.Metal-based anti-diabetic drugs: advances and challenges.Hyphenated techniques as tools for speciation analysis of metal-based pharmaceuticals: developments and applications.Red carpeting the newer antidiabetics.An evidence-based systematic review of vanadium by the Natural Standard Research Collaboration.The potentiality of vanadium in medicinal applications.Antidiabetic agents: past, present and future.Vanadium carcinogenic, immunotoxic and neurotoxic effects: a review of in vitro studies.The role of vanadium in biology.Vanadium Compounds as Pro-Inflammatory Agents: Effects on Cyclooxygenases.Interaction of [VIV O(acac)2 ] with Human Serum Transferrin and Albumin.Perspectives for vanadium in health issues.In vitro and in vivo antitumor effects of the VO-chrysin complex on a new three-dimensional osteosarcoma spheroids model and a xenograft tumor in mice.Bis(acetylacetonato)-oxidovanadium(IV) and sodium metavanadate inhibit cell proliferation via ROS-induced sustained MAPK/ERK activation but with elevated AKT activity in human pancreatic cancer AsPC-1 cells.Influence of Primary Ligands (ODA, TDA) on Physicochemical and Biological Properties of Oxidovanadium (IV) Complexes with Bipy and Phen as Auxiliary Ligands.Oxidovanadium(IV) complexes with chrysin and silibinin: anticancer activity and mechanisms of action in a human colon adenocarcinoma model.Inhibition of human amylin fibril formation by insulin-mimetic vanadium complexes.Structural and redox requirements for the action of anti-diabetic vanadium compounds.Stabilities and Biological Activities of Vanadium Drugs: What is the Nature of the Active Species?
P2860
Q28068342-3C9FA699-F35C-4676-AC7E-FD97B1C5FC1FQ28074241-BC7A1BA5-FF24-4737-97C0-C4BA41B0F1B5Q28649323-6802E3B9-92BF-4BE6-BF3A-C77A8BF6F175Q28655973-CB3396B7-26AA-4CDB-8630-17088F79843BQ30540653-A65D304B-3750-4A8B-84C0-045CAFD58940Q30580717-A2F15659-84D0-4E5B-8809-BF83AC5A78BEQ31128540-2079DC67-D178-48EE-A37F-D5C7D3EBF605Q31135989-28746804-D328-4270-A5BA-4C6ECD3ED42AQ33964023-FD28D1A4-2EC6-4C33-B33A-9418EBB86A5FQ34170125-F98467B2-5370-4FD5-8584-D46AF4C76278Q34180436-48B2A596-E7D5-472F-8766-CDE3171BDC36Q34262663-4D6BB016-92CC-474D-8425-C0FB9F44A64EQ34272841-CE60C3B3-695C-4048-9262-A60F07E03625Q34504189-73235B01-1D65-45C3-8CF9-729475A24492Q35220583-AD635D24-5C0B-4D12-ACEA-DF4FC2564ACEQ35630550-74ACB5F4-9CCC-4C35-AD01-13FA95BF4EA1Q36271101-BAAA867F-DA2A-49F7-A335-6ED124BEEED6Q36453775-79B19180-2253-4672-8BEF-E95DD8E35C5AQ37393323-B32A23E8-3337-4E5F-A928-D9FAA8B6D8D8Q37645135-8C943153-EFAF-4243-9809-C49EF648FECAQ37703251-7F97C73C-A4B9-4218-A0DB-E58505C666BDQ37853432-DA87F524-8077-45FF-9FDC-C563FB3FBBDDQ37900507-CEFC6867-EF0F-490F-A661-1FC2C45B8C4BQ38000483-D112A896-FAAF-492A-A9DC-14311655D672Q38013105-C1369384-5039-454E-86A3-C88E5D811A00Q38034568-FEADFFB6-931A-4E26-B3B8-981672E5CCDCQ38050178-212CC178-09CE-435B-9C67-00ABCF290BBAQ38089737-E284ED3B-5607-4C7D-9CF6-C66B5D6361F3Q38154593-FAA2AD29-8F39-400C-85A6-CE11AB1C12A1Q38327171-671DA853-0635-443D-A9F2-5D36C3502F21Q38520262-C7493DEB-5E65-4E30-B516-0FDBFAA7C0CDQ38708683-15EA9B5C-80BE-442C-8DE1-4E8D82994963Q38742665-813F84DF-21DC-4167-BF4C-7616F79671A0Q38742783-9DC75FDC-B827-4DA4-9A45-82A9A27B6899Q38747030-8C303005-9DCF-41C9-8889-B247692C80BEQ38780536-838EAD49-F9C7-4467-9A69-13DFC1D4236CQ38832743-B8243947-E134-4C87-AC5B-250B52283941Q39006181-25F31273-B4EB-4E31-A02B-5D52825E1F42Q39011814-A2F0B901-7D2B-4F8A-AA79-03A06257DF03Q39237165-F085EC53-78B2-4276-B8BF-AD36F75988C0
P2860
Vanadium treatment of type 2 diabetes: a view to the future.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 24 December 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Vanadium treatment of type 2 diabetes: a view to the future.
@en
Vanadium treatment of type 2 diabetes: a view to the future.
@nl
type
label
Vanadium treatment of type 2 diabetes: a view to the future.
@en
Vanadium treatment of type 2 diabetes: a view to the future.
@nl
prefLabel
Vanadium treatment of type 2 diabetes: a view to the future.
@en
Vanadium treatment of type 2 diabetes: a view to the future.
@nl
P2093
P1476
Vanadium treatment of type 2 diabetes: a view to the future.
@en
P2093
Carl LeBel
Jay Lichter
John H McNeill
Katherine H Thompson
Michael C Scaife
P304
P356
10.1016/J.JINORGBIO.2008.12.003
P50
P577
2008-12-24T00:00:00Z